Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
Taiwan Gastrointestinal Disease and Helicobacter Consortium
Research output: Contribution to journal › Article › peer-review
40Scopus
citations
Fingerprint
Dive into the research topics of 'Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial'. Together they form a unique fingerprint.